MSLE

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

All four participants showed a decline in fat fraction as measured by MRI, with a mean improvement of 3.7% from 49.7% at TRAILHEAD baseline to 46.0% at month 6, suggesting improved muscle composition All four participants showed an increase in TE99C, a measure of maximum effort in upper limbs, with a mean improvement of approximately 34% from a baseline of 16.1 joules/kg to 21.6 joules/kg at TRAILHEAD month 6, suggesting enhanced upper limb activityNear doubling of handgrip strength measured during the 28-day CL-101 study maintained through month 6 of TRAILHEADMean creatine kinase (CK), a biomarker of muscle damage, declined 38% from baseline through month 6 of TRAILHEADSafety profile of SAT

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

SAT-3247 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations for Duchenne muscular dystrophy ("Duchenne" or "DMD")Fast Track is designed to expedite the development/review of new drugs to treat serious or life-threatening conditions and fill unmet medical needsPhase 2 BASECAMP and TRAILHEAD studies ongoing in DMD with additional data expected in 2H 2026 TORONTO, June 29, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat degenerative muscle diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fas

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat degenerative muscle diseases, today announced that new data from its SAT-3247 clinical development program will be featured at the 19th International Congress on Neuromuscular Diseases (ICNMD), taking place July 7–11, 2026, in Florence, Italy, at Fortezza da Basso. Presentations will include a poster highlighting six-month follow-up data from participants who completed the Phase 1b SAT-3247-CL-101 trial and enrolled in the ongoing Phase 2 TRAILHEAD (LT-001) trial. Satellos will also participate

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, announced today the results of its Annual Meeting of Shareholders held June 17, 2026 (the "Meeting"). Satellos is pleased to announce that all the nominees listed in the management information circular dated May 14, 2026 (the "Circular") were elected as directors. Shareholders present at the Meeting or represented by proxy totaled 55.3% of the issued and outstanding common shares of the Company. The results of the vote are detailed below: DirectorVotes Fo

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

TORONTO, May 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that members of the Company management team will participate in the following investor conferences in June. Jefferies Global Healthcare ConferenceDate: Thursday, June 4, 2026Presentation: 11:05 a.m.Location: New York, NY Oppenheimer CNS & Neuro-Muscular SummitDate: Wednesday, June 10Panel: Next-Generation Therapeutics in Genetic Muscle Disorders, 10:15 a.m.Location: Miami, FL The presentation will be available via live webcast on the Event

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026BASECAMP remains on track to complete enrollment in Q3 2026The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years.Current cash available of $69.9M (Cdn $97.5M) provides runway through 2027 TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced financial results and corporate highlights for the first quarter ended March 31, 2026. "The first quarter of

SCHEDULE 13G - Satellos Bioscience Inc. (0001421642) (Subject)

Guggenheim initiated coverage of Satellos Bioscience with a rating of Buy and set a new price target of $23.00

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) (" Satellos " or the " Company "), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton & Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada. Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference. 2026 Bloom Burton & Co. Healthcare Investor ConferenceFormat: Pres

Leerink Partners initiated coverage of Satellos Bioscience with a rating of Outperform and set a new price target of $20.00

S-8 - Satellos Bioscience Inc. (0001421642) (Filer)

40-F - Satellos Bioscience Inc. (0001421642) (Filer)

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker "MSLE" on Feb. 6, 2026 Secured global regulatory clearances and initiated BASECAMP, a placebo-controlled Phase 2 clinical trial of SAT-3247 in boys aged 7 to less than 10 years living with Duchenne muscular dystrophy ("Duchenne" or "DMD") Presented initial functional outcomes from 56 days of treatment in TRAILHEAD (follow-on trial to CL-101) at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, demonstrating that grip strength improvements observed in CL-101 were maintained or improved in TRAILHEAD over an aggregate period of 9 to 13 months Reported pro

Cantor Fitzgerald initiated coverage of Satellos Bioscience with a rating of Overweight

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater improvements in strength observed in participants with greater baseline muscle mass, further supporting evaluation in younger ages in ongoing BASECAMP studyProteomic analysis from the CL-101, 28-day Phase 1a/b study demonstrated reduction in established DMD biomarkers within two weeks of SAT-3247 administrationPreclinical data in facioscapulohumeral muscular dystrophy (FSHD) show enhanced muscle strength, supporting broader clinical potential of SAT-3247Enrollment ongoing in TRAILHEAD and BASECAMP